Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study

International Journal of Cancer

Volumn 137, Issue 9, 2015, Pages 2124-2132

  Mondul, Alison M ^a   Moore, Steven C ^b   Weinstein, Stephanie J ^b   Karoly, Edward D ^c   Sampson, Joshua N ^b   Albanes, Demetrius ^b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c METABOLON INC   (United States)

Author keywords

biomarkers; energy metabolism; lipid metabolism; metabolomics; prostate cancer; serology; TCA cycle; thyroxine; TMAO; Warburg

Indexed keywords

1 STEAROYLGLYCEROPHOSPHOGLYCEROL; 2 HYDROXYBUTYRATE; 2 OXOGLUTARIC ACID; 3 HYDROXYLAURATE; ALPHA TOCOPHEROL; AMINO ACID DERIVATIVE; BETA CAROTENE; BETA HYDROXYISOVALERATE; CITRIC ACID; DEOXYURIDINE; DOCOSADIENOATE; FATTY ACID; GLYCEROPHOSPHOLIPID; GLYCOLITHOCHOLATE SULFATE; HOMOSTACHYDRINE; IMIDAZOLEACETIC ACID; INDOLEBUTYRIC ACID; INOSITOL 1 PHOSPHATASE; NUCLEOTIDE DERIVATIVE; OLEOYLLINOLEOYLGLYCEROPHOSPHOINOSITOL; PHENYLPYRUVIC ACID; PLACEBO; PROPYL 4 HYDROXYBENZOATE SULFATE; SPHINGOMYELIN; STEARIC ACID; TAURO BETA MURICHOLATE; THYROXINE; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XENOBIOTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER PREVENTION; CANCER RISK; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FINLAND; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; TUMOR INVASION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VITAMIN SUPPLEMENTATION; ADENOCARCINOMA; BLOOD; METABOLOME; MIDDLE AGED; PROSTATIC NEOPLASMS;

ADENOCARCINOMA; ALPHA-TOCOPHEROL; BETA CAROTENE; BIOMARKERS, TUMOR; HUMANS; MALE; METABOLOME; METABOLOMICS; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 84939255184     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29576     Document Type: Article

References (42)

1. Brawley OW,. Prostate cancer epidemiology in the United States. World J Urol 2012; 30: 195-200.
2. Al Olama AA, Kote-Jarai Z, Berndt SI, et al., A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014; 46: 1103-9.
3. Nicholson JK, Lindon JC,. Systems biology: metabonomics. Nature 2008; 455: 1054-6.
4. O'Connell TM,. Recent advances in metabolomics in oncology. Bioanalysis 2012; 4: 431-51.
5. Lokhov PG, Dashtiev MI, Moshkovskii SA, et al., Metabolite profiling of blood plasma of patients with prostate cancer. Metabolomics 2010; 6: 156-63.
6. Trock BJ,. Application of metabolomics to prostate cancer. Urol Oncol 2011; 29: 572-81.
7. Mondul AM, Moore SC, Weinstein SJ, et al., 1-Stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling. Metabolomics 2014; 10: 1036-41.
8. The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994; 4: 1-10.
9. Evans AM, DeHaven CD, Barrett T, et al., Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009; 81: 6656-67.
10. Dehaven CD, Evans AM, Dai H, et al., Organization of gc/ms and lc/ms metabolomics data into chemical libraries. J Cheminform 2010; 2: 9
11. Sampson JN, Boca SM, Shu XO, et al., Metabolomics in epidemiology: sources of variability in metabolite measurements and implications. Cancer Epidemiol Biomarkers Prev 2013; 22: 631-40.
12. Efron B, Tibshirani R,. On testing the significance of sets of genes. Ann Appl Stat 2006; 1: 107-29.
13. Subramanian A, Tamayo P, Mootha VK, et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50.
14. Mayers JR, Wu C, Clish CB, et al., Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med 2014; 20: 1193-8.
15. Nomura DK, Long JZ, Niessen S, et al., Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010; 140: 49-61.
16. Santos CR, Schulze A,. Lipid metabolism in cancer. FEBS J 2012; 279: 2610-23.
17. Carracedo A, Cantley LC, Pandolfi PP,. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 2013; 13: 227-32.
18. Huang C, Freter C,. Lipid metabolism, apoptosis and cancer therapy. Int J Mol Sci 2015; 16: 924-49.
19. Warburg O,. On the origin of cancer cells. Science 1956; 123: 309-14.
20. Costello LC, Franklin RB, Feng P,. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005; 5: 143-53.
21. Nomura DK, Lombardi DP, Chang JW, et al., Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol 2011; 18: 846-56.
22. Ito K, Suda T,. Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol 2014; 15: 243-56.
23. Schlaepfer IR, Rider L, Rodrigues LU, et al, Lipid catabolism via cpt1 as a therapeutic target for prostate cancer. Mol Cancer Ther 2014; 13: 2361-71.
24. Freeman MR, Cinar B, Lu ML,. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 2005; 16: 273-9.
25. Menendez JA,. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim Biophys Acta 2010; 1801: 381-91.
26. Tsui MM, York JD,. Roles of inositol phosphates and inositol pyrophosphates in development, cell signaling and nuclear processes. Adv Enzyme Regul 2010; 50: 324-37.
27. Scott SA, Mathews TP, Ivanova PT, et al., Chemical modulation of glycerolipid signaling and metabolic pathways. Biochim Biophys Acta 2014; 1841: 1060-84.
28. Cinar B, Mukhopadhyay NK, Meng G, et al., Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to akt1 in membrane raft microdomains. J Biol Chem 2007; 282: 29584-93.
29. Costello LC, Franklin RB,. The intermediary metabolism of the prostate: A key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000; 59: 269-82.
30. Wang XZ, Wang B, Gao ZQ, et al., 1H-MRSI of prostate cancer: The relationship between metabolite ratio and tumor proliferation. Eur J Radiol 2010; 73: 345-51.
31. Riches SF, Payne GS, Morgan VA, et al., Multivariate modelling of prostate cancer combining magnetic resonance derived t2, diffusion, dynamic contrast-enhanced and spectroscopic parameters. Eur Radiol 2015; 25: 1247-1256.
32. Mullen AR, Hu Z, Shi X, et al., Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep 2014; 7: 1679-90.
33. Thomas MA, Nagarajan R, Huda A, et al., Multidimensional mr spectroscopic imaging of prostate cancer in vivo. NMR Biomed 2014; 27: 53-66.
34. Koeth RA, Wang Z, Levison BS, et al., Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19: 576-85.
35. Bae S, Ulrich CM, Neuhouser ML, et al., Plasma choline metabolites and colorectal cancer risk in the women's health initiative observational study. Cancer Res 2014; 74: 7442-52.
36. Mondul AM, Weinstein SJ, Bosworth T, et al., Circulating thyroxine, thyroid-stimulating hormone, and hypothyroid status and the risk of prostate cancer. PLoS One 2012; 7: e47730
37. Cross AJ, Boca S, Freedman ND, et al., Metabolites of tobacco smoking and colorectal cancer risk. Carcinogenesis 2014; 35: 1516-22.
38. Bonovas S, Filioussi K, Sitaras NM., Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123: 899-904.
39. Boudreau DM, Yu O, Johnson J,. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010; 9: 603-21.
40. Crowe FL, Appleby PN, Travis RC, et al., Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. J Natl Cancer Inst 2014; 106.
41. Pienta KJ, Esper PS,. Risk factors for prostate cancer. Ann Intern Med 1993; 118: 793-803.
42. Etzioni R, Cha R, Feuer EJ, et al., Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998; 148: 775-85.